/ /

  • linkedin
  • Increase Font
  • Sharebar

    New glaucoma therapy offers first drug option in years

    Latanoprostene bunod increases outflow through the trabecular meshwork and Schlemm's canal

     

    Changing glaucoma landscape

    Glaucoma specialists have been clamoring for new treatment options for years.

    “Open-angle glaucoma is an incurable disease and invariably patients need adjustments, and Vyzulta is probably going to be another excellent tool for us to have in our tool chest,” Dr. Bacharach said.

    How will latanoprostene bunod stack up in the market remains to be seen—there have been no head-to-head clinical studies against other newly approved therapies.

    References:

    1. Weinreb RN, Ong T, Scassellati Sforzolini B, et al. A randomized, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma: the VOYAGER study. Br J Ophthalmol 2015;99:738–745.

    2. Kawase K, Vittitow JL, Weinreb RN, Araie M, Group JS. Long-term Safety and Efficacy of Latanoprostene Bunod 0.024% in Japanese Subjects with Open-Angle Glaucoma or Ocular Hypertension: The JUPITER Study. Adv Ther 2016;33:1612-1627.

    New Call-to-action

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Poll

    View Results